Pseudovirus News and Research

RSS

Development of disinfection process based on ozone for highly efficient inactivation of SARS-CoV-2

This study aimed to evaluate the ozone capacity generated within a newly developed disinfection chamber to eradicate SARS-CoV-2 from porous materials and non-porous materials like glass.

12 Oct 2021

The role of inhibiting palmitoylation of the SARS-CoV-2 spike protein on viral infectivity

It is demonstrated that palmitoylation of the first five cysteine residues of the C-terminal domain of the SARS-CoV-2 spike protein facilitates cell entry and the formation of syncytia.

11 Oct 2021

Moderna COVID vaccine booster dose results in immune memory

A recent study presents evidence that a booster dose of the Moderna vaccine can induce a robust memory immune response against COVID-19.

6 Oct 2021

Using a new public antibody to understand SARS-CoV-2 neutralization

SARS-CoV-2 infects host cells by binding to the angiotensin convertase 2 receptor (ACE2) on the cell surface through its trimeric spike (S) protein. SARS-CoV enters host human cells through endosomes, while SARS-CoV-2 enters through the cell surface and endosomes. The present study published in the journal “Cell Reports” aimed to understand the mechanisms of SARS-CoV-2 antibody neutralization to facilitate the development of therapeutic interventions for COVID-19.

4 Oct 2021

Structure of monoclonal antibody that can potently neutralize SARS-CoV-2 and variants of concern

A new preprint deals with the analysis of the monoclonal antibody J08, which was capable of powerful neutralization of the wildtype SARS-CoV-2, and its VOCs.

1 Oct 2021

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Is one COVID vaccine better than the other? Four current vaccines — Moderna, Pfizer-BioNTech, Johnson & Johnson, and AstraZeneca — are highly effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but a new medRxiv* study suggests the level of protection varies.

30 Sep 2021

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

A new study discusses the development of dedicated reagents against the SARS-CoV-2 spike protein through the use of an automated CLEIA system.

28 Sep 2021

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new study discusses the isolation of two variants of concern (VOCs) from an immunocompromised COVID-19 patient.

27 Sep 2021

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

New research discusses the development of soluble prefusion-stabilized spike trimers (CoV2 preS dTM) comprising adjuvant AS03.

27 Sep 2021

SARS-CoV-2 entry inhibitors show antiviral activity

A new study used a combination of a computer-aided drug design approach and cell-based in vitro assays to identify five potential SARS-CoV-2 inhibitors.

27 Sep 2021

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

Twist Bioscience Corporation (Nasdaq: TWST) today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19.

25 Sep 2021

People with natural immunity and subsequent mRNA vaccination can neutralize viral particles capable of resisting vaccine-induced antibodies

New research suggests SARS-CoV-2 spike protein substitution mutations can create a replication-defective viral particle that makes the virus resistant to vaccine-induced antibodies.

23 Sep 2021

New cell-free antibody generation platform successfully creates neutralizing antibodies effective against SARS-CoV-2

Researchers from the Broad Institute of MIT and Harvard have created a cell-free nanobody engineering platform that can produce antibodies effectively and quickly.

21 Sep 2021

Role of extracellular vesicles embedded with engineered ACE2 in the neutralization of the SARS-CoV-2 pseudovirus

Researchers discuss the preparation and characterization of EVs-ACE2, along with the production and characterization of SARS-CoV-2 S-pseudovirus.

20 Sep 2021

Research on SARS-CoV-2 and dendritic cells may explain why virus is so virulent

In a recent study released on the bioRxiv* preprint server, the researchers suggest that an aberrant inflammatory reaction associated with COVID-19 could be a result of escape from direct sensing by toll-like receptors (TLRs). Moreover, the researchers indicate that this phenomenon might underlie the lack of efficient immunity to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) early during infection.

20 Sep 2021

Study looks at exposure to different SARS-CoV-2 variants and immune response

Researchers compared the responses against several SARS-CoV-2 VoCs in sera from individuals exposed to variant infection, vaccination, or both.

15 Sep 2021

Efficient non-neutralizing antibody to SARS-CoV-2 spike NTD that operates via Fc receptor-mediated pathway

This study revealed that the CV3-13 antibody can mediate Fc effector functions against S protein-expressing cells.

13 Sep 2021

Discovery of diverse sarbecovirus broadly neutralizing antibodies from SARS-CoV-2 “infected-vaccinated” humans

Scientists were inspired by the robust serum nAb responses in people who recovered from natural SARS-CoV-2 infection and were later vaccinated using mRNA vaccine. They isolated and characterized bnAbs from two COVID-19 convalescent donors who were recently vaccinated. These isolated bnAbs were found to be highly potent against sarbecoviruses. This research is available on the bioRxiv* preprint server.

13 Sep 2021

No evidence of pre-existing antibody and B cell immunity against SARS-CoV-2 in unexposed adults

A group of researchers analyzed the B cell response to SARS-CoV-2 in unexposed individuals.

10 Sep 2021

Mu SARS-CoV-2 variant highly resistant to neutralization by convalescent and vaccinated sera

Researchers in Japan have warned that the Mu (B.1.621) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – appears to be highly resistant to neutralization by sera from convalescent or vaccinated individuals.

8 Sep 2021

Pseudovirus News and Research

Development of disinfection process based on ozone for highly efficient inactivation of SARS-CoV-2

The role of inhibiting palmitoylation of the SARS-CoV-2 spike protein on viral infectivity

Moderna COVID vaccine booster dose results in immune memory

Using a new public antibody to understand SARS-CoV-2 neutralization

Structure of monoclonal antibody that can potently neutralize SARS-CoV-2 and variants of concern

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

Chronic COVID-19 and divergent variants of SARS-CoV-2

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

SARS-CoV-2 entry inhibitors show antiviral activity

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

People with natural immunity and subsequent mRNA vaccination can neutralize viral particles capable of resisting vaccine-induced antibodies

New cell-free antibody generation platform successfully creates neutralizing antibodies effective against SARS-CoV-2

Role of extracellular vesicles embedded with engineered ACE2 in the neutralization of the SARS-CoV-2 pseudovirus

Research on SARS-CoV-2 and dendritic cells may explain why virus is so virulent

Study looks at exposure to different SARS-CoV-2 variants and immune response

Efficient non-neutralizing antibody to SARS-CoV-2 spike NTD that operates via Fc receptor-mediated pathway

Discovery of diverse sarbecovirus broadly neutralizing antibodies from SARS-CoV-2 “infected-vaccinated” humans

No evidence of pre-existing antibody and B cell immunity against SARS-CoV-2 in unexposed adults

Mu SARS-CoV-2 variant highly resistant to neutralization by convalescent and vaccinated sera

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News